Sugi Predict

Sugi Predict / Compounds / SCHEMBL4723266

SCHEMBL4723266

SCHEMBL4723266

c1ccc2c([C]3CCC3)cccc2c1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ NISCH Q9Y2I1 1/20 0.43
▸ BRD4 O60885 1/20 0.43
▸ GALR1 P47211 1/20 0.42
▸ ALDH1A1 P00352 5/20 0.42
▸ CYP2A6 P11509 3/20 0.42
▸ HSD17B10 Q99714 3/20 0.42
▸ TSHR P16473 2/20 0.42
▸ TDP1 Q9NUW8 1/20 0.42
▸ LMNA P02545 2/20 0.41
▸ MAPT P10636 2/20 0.41
▸ HTT P42858 2/20 0.41
▸ SMN1; SMN2 Q16637 1/20 0.41
▸ NPSR1 Q6W5P4 1/20 0.41
▸ KDM4E B2RXH2 2/20 0.40
▸ GAA P10253 2/20 0.40
▸ PTPN1 P18031 1/20 0.40
▸ ALPL P05186 1/20 0.40
▸ CYP1A2 P05177 2/20 0.39
▸ HPGD P15428 2/20 0.39
▸ CYP3A4 P08684 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL497993 0.95 NISCH (0.43) NISCHBRD4GALR1ALDH1A1CYP2A6
SCHEMBL1783499 0.93 NISCH (0.42) NISCHBRD4GALR1ALDH1A1CYP2A6
SCHEMBL28753798 0.93 NISCH (0.42) NISCHBRD4GALR1ALDH1A1CYP2A6
SCHEMBL497769 0.91 ALDH1A1 (0.46) NISCHGALR1ALDH1A1CYP2A6HSD17B10
SCHEMBL29186323 0.82 NISCH (0.43) NISCHBRD4GALR1ALDH1A1CYP2A6
SCHEMBL9044714 0.81 NISCH (0.47) NISCHBRD4ALDH1A1CYP2A6HSD17B10
SCHEMBL4723098 0.81 ALDH1A1 (0.39) ALDH1A1CYP2A6HSD17B10TSHRLMNA
SCHEMBL29109596 0.79 ALDH1A1 (0.38) BRD4ALDH1A1HSD17B10TSHRTDP1
SCHEMBL25302086 0.77 ALDH1A1 (0.59) NISCHALDH1A1CYP2A6HSD17B10TSHR
SCHEMBL29350007 0.77 ALDH1A1 (0.59) NISCHALDH1A1CYP2A6HSD17B10TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 71 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1654225-A4 MELANIN CONCENTRATING HORMONE RECEPTOR ANTAGONISTS AMGEN INC (US) 2007-11-28 — — EP claimed
EP-1654225-A2 MELANIN CONCENTRATING HORMONE RECEPTOR ANTAGONISTS Amgen, Inc. (US) 2006-05-10 — — EP claimed
US-20050256161-A1 Melanin concentrating hormone receptor antagonists AMGEN INC. 2005-11-17 — — US claimed
WO-2005019240-A2 MELANIN CONCENTRATING HORMONE RECEPTOR ANTAGONISTS AMGEN, INC. (US) 2005-03-03 — — WO claimed
CN-114944459-B Organic electroluminescent device 长春海谱润斯科技股份有限公司 2024-07-02 — — CN disclosed
CN-118139509-A Organic electroluminescent device 长春海谱润斯科技股份有限公司 2024-06-04 — — CN disclosed
CN-117924268-A Heterocyclic compound and organic electroluminescent device thereof 长春海谱润斯科技股份有限公司 2024-04-26 — — CN disclosed
CN-117903188-A Heterocyclic compound and organic electroluminescent device thereof 长春海谱润斯科技股份有限公司 2024-04-19 — — CN disclosed
CN-117903189-A Carbazole compound and organic electroluminescent device thereof 长春海谱润斯科技股份有限公司 2024-04-19 — — CN disclosed
CN-117756648-A Aromatic amine compound and organic electroluminescent device thereof 长春海谱润斯科技股份有限公司 2024-03-26 — — CN disclosed
CN-117677216-A Organic electroluminescent device 长春海谱润斯科技股份有限公司 2024-03-08 — — CN disclosed
CN-117677215-A Organic electroluminescent device 长春海谱润斯科技股份有限公司 2024-03-08 — — CN disclosed
WO-2006103544-A2 4-PIPERAZINYLTHIENO [2, 3-D] PYRIMIDINE COMPOUNDS AS PLATELET AGGREGATION INHIBITORS PHARMACIA & UPJOHN COMPANY LLC (US) 2006-10-05 — — WO disclosed
WO-2006103545-A1 4-PIPERAZINYLTHIENO [2,3-D] PYRIMIDINE COMPOUNDS AS PLATELET AGGREGATION INHIBITORS PHARMACIA & UPJOHN COMPANY LLC (US) 2006-10-05 — — WO disclosed
WO-2006100591-A1 4-PIPERAZINNYLTHIENO [2,3-D] PYRIMIDINE COMPOUNDS AS PLATELET AGGREGATION INHIBITORS PHARMACIA & UPJOHN COMPANY LLC (US) 2006-09-28 — — WO disclosed
WO-2006079916-A1 THIENO [2,3-D] PYRIMIDINE COMPOUNDS AS INHIBITORS OF ADP-MEDIATED PLATELETS AGGREGATION PHARMACIA & UPJOHN COMPANY LLC (US) 2006-08-03 — — WO disclosed
EP-1654225-A2 MELANIN CONCENTRATING HORMONE RECEPTOR ANTAGONISTS Amgen, Inc. (US) 2006-05-10 — — EP disclosed
US-20050256161-A1 Melanin concentrating hormone receptor antagonists AMGEN INC. 2005-11-17 — — US disclosed
WO-2005019240-A2 MELANIN CONCENTRATING HORMONE RECEPTOR ANTAGONISTS AMGEN, INC. (US) 2005-03-03 — — WO disclosed
US-20040067436-A1 Polymerizable silicon-containing compound, manufacturing method, polymer, resist composition and patterning process SHIN-ETSU CHEMICAL CO., LTD. (JP) 2004-04-08 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050256161-A1 Melanin concentrating hormone receptor antagonists MCHR1, MC1R, NPY1R NISCH 1322/4885BRD4 4839/4885GALR1 28/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.